Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1Available 1Approved for marketing 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 2Expanded_access 2

Sponsor

Cancer Type

Endocrine 4CNS 4NET 2

Conditions

Pheochromocytoma 5Paraganglioma 4Neuroblastoma 4Neuroendocrine Tumors 2Neuroectodermal Tumors 1Neoplasms 1Disease 1

Interventions

3-Iodobenzylguanidine 4spartalizumab 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1belzutifan 1ONC206 1Nivolumab 1Lutetium-177 1Lutetium 1Iodine-131 1Everolimus 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Paraganglioma × 3-Iodobenzylguanidine × Clear all
NCT01590680 2023-02-28

Expanded Access Protocol Using 131I-MIBG

Jubilant DraxImage Inc.

Available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Approved for marketing
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡